Skip to main content
OpenTrials

Clinical trial condition

Relapsed Multiple Myeloma

Explore clinical trials studying Relapsed Multiple Myeloma. Study availability and eligibility vary by location and protocol.

26 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Relapsed Multiple Myeloma trial results

Completed

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

NCT04398485

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • University of California San Diego Moores Cancer Center La Jolla, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • UCLA Rrmc Los Angeles, California, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
View Trial Details
Completed

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

NCT04434469

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
  • LIVERPOOL HOSPITAL; HAEMATOLOGY; Ingham Institute for Medical Research Liverpool, New South Wales, Australia
  • Royal Adelaide Hospital; Haematology Clinical Trials Adelaide, South Australia, Australia
  • St. Vincent's Hospital Melbourne Fitzroy, South Australia, Australia
View Trial Details
Completed

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT01564537

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • University of Arkansas Medical Sciences Little Rock, Arkansas, United States
  • Pacific Cancer Medical Center Inc Anaheim, California, United States
  • West Contra Costa Healthcare District Berkeley, California, United States
  • University of Florida Gainesville, Florida, United States
View all 24 locations
View Trial Details
Completed

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

NCT01080391

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Mayo Clinic Scottsdale, Arizona, United States
  • Providence St. Joseph Medical Center Burbank, California, United States
  • St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare Santa Rosa, California, United States
  • Stanford University Stanford, California, United States
View all 127 locations
View Trial Details
Completed

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

NCT00603447

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Pacific Shores Medical Group Long Beach, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
View Trial Details
Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital Lake Success, New York, United States
  • Gabrail Cancer Center Canton, Ohio, United States
  • Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic Nashville, Tennessee, United States
View all 13 locations
View Trial Details

Related conditions